«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 08

Page:

1568-1572

Research Field:

Publishing date:

Info

Title:

Research progress of thyroid toxicity related to immune checkpoint inhibitors

Author(s):

LI Hongmin¹; ZHAO Yongcai²; GUO Peng¹; WANG Yanrong¹; CHEN Ran¹; LIU Ying¹

1.Department of Phase I Clinical Trial Research;2.the Fourth Department of Endocrinology and Diabetes,Cangzhou Central Hospital,Hebei Cangzhou 061000,China.

Keywords:

immune checkpoint inhibitors; immune-related adverse effects; thyroid toxicity

PACS:

R730.5

DOI:

10.3969/j.issn.1672-4992.2023.08.034

Abstract:

Immune checkpoint inhibitors (ICIs),as a powerful anticancer method of tumor immunotherapy,have been increasingly applied in tumor therapy.It kills tumor cells by relieving the inhibitory effect of tumor cells on immune cells,but in the process of action,due to the over-activation of immune cells,autoimmune reactions occur in multiple systems of the body,including the endocrine system,namely immune-related adverse events (irAEs).Thyroid toxicity is a common endocrine toxicity,including hypothyroidism,hyperthyroidism,thyroiditis and even thyroid crisis.With the wide application of ICIs in clinic,the occurrence of thyroid toxicity is bound to be increasing.This article reviews its epidemiology,pathogenesis,clinical manifestations and clinical management,in order to improve the understanding of clinicians and improve the quality of cancer patients' life.

References:

£Û1£ÝFERRARI SM,FALLAHI P,GALETTA F,et al.Thyroid disorders induced by checkpoint inhibitors£ÛJ£Ý.Rev Endocr Metab Disord,2018,19(4):325-333.
£Û2£ÝÍõ¼Ñ»Û,³Â¹«çü.»ùÓÚPD-1/PD-L1ÒÖÖƼÁµÄ·ÇСϸ°û·Î°©ÃâÒßÖÎÁÆÔ¤²â±êÖ¾ÎïµÄÑо¿½øÕ¹£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ,2021,29(10):1822-1825. WANG JH,CHEN GY.Advances in the study of predictive markers of immunotherapy for non-small cell lung cancer based on PD-1/PD-L1 inhibitors£ÛJ£Ý.Modern Oncology,2021,29(10):1822-1825.
£Û3£ÝBYUN DJ,WOLCHOK JD,ROSENBERG LM,et al.Cancer immunotherapy immune checkpoint blockade and associated endocrinopathies£ÛJ£Ý.Nat Rev Endocrinol,2017,13(4):195-207.
£Û4£ÝBARROSO SR,BARRY WT,GARRIDO AC,et al.Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens:A systematic review and Meta-analysis£ÛJ£Ý.JAMA Oncol,2018,4(2):173-182.
£Û5£ÝAGRAWAL L,BACAL A,JAIN S,et al.Immune checkpoint inhibitors and endocrine side effects,a narrative review£ÛJ£Ý.Postgrad Med,2020,132(2):206-214.
£Û6£ÝCHOI J,LEE SY.Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors£ÛJ£Ý.Immune Netw,2020,20(1):e9.
£Û7£ÝBARROSO SR,OTT PA,HOID FS,et al.Endocrine dysfunction induced by immune checkpoint inhibitors:Practical recommendations for diagnosis and clinical management£ÛJ£Ý.Cancer,2018,124(6):1111-1121.
£Û8£ÝVARRICCHI G,LOFFREDO S,MARONE G,et al.The immune landscape of thyroid cancer in the context of immune checkpoint inhibition£ÛJ£Ý.Int J Mol Sci,2019,20(16):3934.
£Û9£ÝILLOUZ F,DRUI D,CARON P,et al.Expert opinion on thyroid complications in immunotherapy£ÛJ£Ý.Ann Endocrinol(Paris),2018,79(5):555-561.
£Û10£ÝASCIERTO PA,VECCHIO MD,ROBERT C,et al.Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma:a randomised,double-blind,multicentre,phase 3 trial£ÛJ£Ý.Lancet Oncol,2017,18(5):611-622.
£Û11£ÝORLOV S,SALARI F,KASHAT L,et al.Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies£ÛJ£Ý.J Clin Endocrinol Metab,2015,100(5):1738-1741.
£Û12£ÝMIN L,VAIDYA A,BECKER C,et al.Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy£ÛJ£Ý.Eur J Endocrinol,2011,164(2):303-307.
£Û13£ÝYAMADA H,OKAJIMA F,ONDA T,et al.New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer:a case report£ÛJ£Ý.BMC Endocr Disord,2020,20(1):132.
£Û14£ÝCAMPREDON P,IMBERT P,MOULY C,et al.Severe inflammatory ophthalmopathy in a euthyroid patient during Nivolumab treatment£ÛJ£Ý.Eur Thyroid J,2018,7(2):84-87.
£Û15£ÝBAI XF,CHEN XY,WU XH,et al.Immune checkpoint inhibitor-associated thyroid dysfunction:a disproportionality analysis using the WHO Adverse Drug Reaction Database,VigiBase£ÛJ£Ý.European Journal of Endocrinology,2020,182(1):1-9.
£Û16£ÝYONEZAKI K,KOBAYASHI T,IMACHI H,et al.Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus:a case report£ÛJ£Ý.Journal of Medical Case Reports,2018,12(1):171.
£Û17£ÝGEORGES JL,NORMAND JP,LENORMAND ME,et al.Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease£ÛJ£Ý.Eur Heart J,1992,13(1):129-132.
£Û18£ÝHARALDSDOTTIR S,LI Q,VILLALONA-CALERO MA,et al.Case of sorafenib-induced thyroid storm£ÛJ£Ý.J Clin Oncol,2013,31(16):e262-264.
£Û19£ÝVILLADOLID J,AMIN A.Immune checkpoint inhibitors in clinical practice:update on management of immune-related toxicities£ÛJ£Ý.Transl Lung Cancer Res,2015,4(5):560-575.
£Û20£ÝFERRARI SM,ELIA G,PIAGGI S,et al.CCL2 is modulated by cytokines and PPAR-¦Ã in anaplastic thyroid cancer£ÛJ£Ý.Anticancer Agents Med Chem,2018,18(3):458-466.
£Û21£ÝWIN MA,THEIN KZ,QDAISAT A,et al.Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism£ÛJ£Ý.Am J Emerg Med,2017,35(7):1039.e5-1039.e7.
£Û22£ÝZENG MF,CHEN LL,YE HY,et al.Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy:case report and review£ÛJ£Ý.Medicine(Baltimore),2017,96(44):e8426.
£Û23£ÝANTONELLI A,FERRARI SM,FALLAHI P.Current and future immunotherapies for thyroid cancer£ÛJ£Ý.Expert Rev Anticancer Ther,2018,18(2):149-159.
£Û24£ÝALHUSSEINI M,SAMANTRAY J.Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents:Insights on underlying mechanisms£ÛJ£Ý.Exp Clin Endocrinol Diabetes,2017,125(4):267-269.
£Û25£ÝKOTWAL A,GUSTAFSON MP,BORNSCHLEGL S,et al.Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations£ÛJ£Ý.Thyroid,2020,30(10):1440-1450.
£Û26£ÝYAMAUCHI I,SAKANE Y,FUKUDA Y,et al.Clinical features of nivolumab-induced thyroiditis:a case series study£ÛJ£Ý.Thyroid,2017,27(7):894-901.
£Û27£ÝINOUSE H,PARK JH,KIYOTANI K,et al.Intratumoral expression levels of PD-L1,GZMA,and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma£ÛJ£Ý.Oncoimmunology,2016,5(9):e1204507.
£Û28£ÝZHANG Y,GAROFANO F,WU XL,et al.Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics£ÛJ£Ý.Invest New Drugs,2020,38(6):1717-1729.
£Û29£ÝSZNOL M,POSTOW MA,DAVIES MJ,et al.Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management£ÛJ£Ý.Cancer Treat,2017,58:70-76.
£Û30£ÝCORSELLO SM,BARNABEI A,MARCHETTI P,et al.Endocrine side effects induced by immune checkpoint inhibitors£ÛJ£Ý.J Clin Endocrinol Metab,2013,98(4):1361-1375.
£Û31£ÝSPAIN L,DIEM S,LARKIN J.Management of toxicities of immune checkpoint inhibitors£ÛJ£Ý.Cancer Treat Rev,2016,44:51-60.
£Û32£ÝHAANEN J,CARBONNEL F,ROBERT C,et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up£ÛJ£Ý.Ann Oncol,2018,29(Suppl 4):iv264-iv266.
£Û33£ÝBRILLI L,DANIELLI R,CAMPANILE M,et al.Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy£ÛJ£Ý.J Endocrinol Invest,2021,44(8):1719-1726.
£Û34£ÝFRELAU A,PALARD NX,JALI E,et al.Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies£ÛJ£Ý.Cancer Immunol Immunother,2021,70(3):679-687.
£Û35£ÝÖлªÒ½Ñ§»áÄÚ·ÖÃÚѧ·Ö»á.³ÉÈ˼××´ÏÙ¹¦ÄܼõÍËÖ¢ÕïÖÎÖ¸ÄÏ£ÛJ£Ý.ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾,2017,33(2):167-180. Endocrinology branch of Chinese Medical Association.Guidelines for the diagnosis and treatment of adult hypothyroidism£ÛJ£Ý.Chin J Endocrinol Metab,2017,33(2):167-180.
£Û36£ÝCHAMPIAT S,LAMBOTTE O,BARREAU E,et al.Management of immune checkpoint blockade dysimmune toxicities:a collaborative position paper£ÛJ£Ý.Ann Oncol,2016,27(4):559-574.
£Û37£ÝKeytruda¡k£¨Pembrolizumab£©injection
£ÛZ£Ý.USA:Merck & Co,Inc,2015.
£Û38£ÝNAIDOO J,PAGE DB,LI BT,et al.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies£ÛJ£Ý.Ann Oncol,2015,26(12):2375-2391.
£Û39£ÝBRAHMER JR,LACCHETTI C,SCHNEIDER BJ,et al.Management of immune related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline£ÛJ£Ý.J Clin Oncol,2018,36(17):1714-1768.
£Û40£ÝÅíÖÇ,Ô¬¼Ò¼Ñ,ÍõÕýº½,µÈ.ASCO/NCCNÃâÒßÖÎÁƶ¾ÐÔ¹ÜÀíÖ¸ÄϽâ¶Á£ÛJ£Ý.Ö×Áö×ÛºÏÖÎÁƵç×ÓÔÓÖ¾,2018,4(2):38-47. PENG Z,YUAN JJ,WANG ZH,et al.Comments on ASCO/NCCN management guidelines of toxicities from immunotherapy£ÛJ£Ý.Journal of Multidisciplinary Cancer Management (Electronic Version),2018,4(2):38-47.
£Û41£ÝHORVAT TZ,ADEL NG,DANG TO,et al.Immune-related adverse events,need for systemic immunosuppression,and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center£ÛJ£Ý.J Clin Oncol,2015,33(28):3193-3198.
£Û42£Ý¶ÎÁ¶,ÍõÁÖ½Ü,˹ÏþÑà,µÈ.ÃâÒß¼ì²éµãÒÖÖƼÁÏà¹ØÄÚ·ÖÃÚ²»Á¼·´Ó¦µÄÁÙ´²ÕïÖν¨Òé£ÛJ£Ý.Öйú·Î°©ÔÓÖ¾,2019,22(10):649-652. DUAN L,WANG LJ,SI XY,et al.Clinical diagnosis and treatment of immune-related adverse events of endocrine system related to immune checkpoint inhibitors£ÛJ£Ý.Chin J Lung Cancer,2019,22(10):649-652.
£Û43£ÝWRIGHT JJ,POWERS AC,JOHNSON DB,et al.Endocrine toxicities of immune checkpoint inhibitors£ÛJ£Ý.Nat Rev Endocrinol,2021,17(7):389-399.

Memo

Memo:

ºÓ±±Ê¡Öصã¿Æ¼¼Ñо¿¼Æ»®£¨±àºÅ£º20200340£©

Common functions

Last Update: 1900-01-01